General Provisions - The purpose of the system is to strengthen the management of shares held by the board of directors and senior management of Nanjing Mylande Medical Technology Co., Ltd. and to clarify relevant procedures based on laws and regulations [1][2] - This system applies to the management of shares held and traded by the company's directors and senior management [2] Prohibited Trading Activities - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or within six months after leaving the company [2][3] - Specific periods during which directors and senior management cannot trade shares include 15 days before the annual and semi-annual report announcements and 5 days before quarterly reports [3] Trading Operations and Restrictions - Directors and senior management must notify the board secretary in writing of their trading plans in advance, and cannot proceed without feedback from the board secretary [4][5] - The maximum number of shares that can be transferred annually by directors and senior management is limited to 25% of their total holdings, with exceptions for certain circumstances [5][6] Reporting and Disclosure Management - Changes in shareholdings must be reported to the board secretary within two trading days and announced on the Shanghai Stock Exchange [10][11] - A reduction plan must be disclosed 15 days prior to the first sale, including details such as the number of shares and the reason for the reduction [9][10] Responsibilities and Penalties - Violations of trading regulations may result in the company recovering profits from illegal trades and reporting the situation to regulatory authorities [11][12] - Serious violations can lead to penalties from the China Securities Regulatory Commission, including market bans for responsible individuals [12][13] Additional Provisions - The system will be implemented upon approval by the company's board of directors and will be interpreted by the board [14][15]
麦澜德: 《董事和高级管理人员所持本公司股份及其变动管理制度》(2025年8月)